BAM
GLMD icon

Brave Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Brave Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64
Closed -$4K – 154
2022
Q3 		$4K Hold
64
– – ﹤0.01% 149
2022
Q2 		$8K Hold
64
– – ﹤0.01% 145
2022
Q1 		$18K Hold
64
– – 0.01% 155
2021
Q4 		$21K Hold
64
– – 0.01% 152
2021
Q3 		$32K Hold
64
– – 0.01% 149
2021
Q2 		$35K Buy
+64
New +$34.8K 0.01% 152

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brave Asset Management's GLMD Position: Q4 2022 in Review

Brave Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2022, closing a stake of 64 shares — an estimated $4K sold.

Brave Asset Management first reported a position in GLMD in Q2 2021 and held it in 6 quarters. The position peaked at $35K in Q2 2021. 22 funds tracked by Wall St. Rank hold GLMD as of Q4 2022.

  • Brave Asset Management reported no remaining Galmed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Brave Asset Management sold 64 Galmed Pharmaceuticals shares in Q4 2022, an estimated $4K.
  • Brave Asset Management first reported a position in Galmed Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Brave Asset Management's Galmed Pharmaceuticals position peaked at $35K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2022.

Based on Brave Asset Management's 13F filing for Q4 2022, filed 20 Jan 2023.